Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia

23Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We analyzed the expression of the inhibitor of apoptosis survivin by immunocytochemistry in bone marrow cells from patients with chronic myelomonocytic leukemia (CMML) to evaluate possible abnormalities in comparison with other myelodysplastic (MDS) and myeloproliferative syndromes, and to investigate a possible correlation between survivin expression and altered apoptosis or proliferation, or relevant laboratory and clinical findings. Thirty-four patients with CMML [18 MDS-CMML and 16 myeloproliferative disorder (MPD)-CMML], 90 with MDS, 41 with acute myeloid leukemia (AML), 19 with chronic MPD and 25 control subjects were studied. In normal samples survivin was never detectable. In CMML survivin levels higher than in MDS and AML (P < 0.0001), but similar to those found in MPD were observed. In CMML and MDS apoptosis was significantly higher compared to normal controls and all other subtypes of leukemias (P < 0.0001). Proliferation did not differ significantly in normal controls, MDS and CMML; the lowest levels were observed in AML and MPD (P < 0.0001). In CMML there was no correlation between survivin expression and blast cell percentage, apoptosis or proliferation, FAB or WHO subgroup. Proliferation was higher in MDS-CMML and tended to correlate with overall survival. CMML-2 cases with higher survivin expression showed higher evolution rate and shorter survival. In conclusion, CMML is characterized by high proliferation and apoptosis. Survivin overexpression, by disrupting the balance between cell proliferation/differentiation and apoptosis, may play an important role in its pathophysiology. The detection of survivin-deregulated expression may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments. © 2006 The Authors.

References Powered by Scopus

International scoring system for evaluating prognosis in myelodysplastic syndromes

4024Citations
N/AReaders
Get full text

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

3096Citations
N/AReaders
Get full text

Control of apoptosis and mitotic spindle checkpoint by survivin

1775Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Phase i study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias

37Citations
N/AReaders
Get full text

Expression of survivin and cortactin in colorectal adenocarcinoma: Association with clinicopathological parameters

34Citations
N/AReaders
Get full text

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: Does anything work?

33Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Invernizzi, R., Travaglino, E., Benatti, C., Malcovati, L., Porta, M. D., Cazzola, M., & Ascari, E. (2006). Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. European Journal of Haematology, 76(6), 494–501. https://doi.org/10.1111/j.0902-4441.2006.t01-1-EJH2588.x

Readers' Seniority

Tooltip

Researcher 10

71%

PhD / Post grad / Masters / Doc 3

21%

Professor / Associate Prof. 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

36%

Agricultural and Biological Sciences 3

27%

Immunology and Microbiology 3

27%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Save time finding and organizing research with Mendeley

Sign up for free